Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (548) 548
Newsletter (25) 25
Publication (15) 15
Newspaper Article (12) 12
Book Chapter (6) 6
Book Review (6) 6
Magazine Article (6) 6
Conference Proceeding (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
saxagliptin (565) 565
index medicus (280) 280
type 2 diabetes (243) 243
humans (238) 238
diabetes mellitus, type 2 - drug therapy (187) 187
sitagliptin (184) 184
diabetes (171) 171
adamantane - analogs & derivatives (150) 150
metformin (143) 143
endocrinology & metabolism (126) 126
pharmacology & pharmacy (121) 121
male (120) 120
vildagliptin (112) 112
dipeptidyl-peptidase iv inhibitors - therapeutic use (109) 109
female (104) 104
drug therapy (96) 96
hypoglycemic agents - therapeutic use (96) 96
dipeptidyl peptidase-4 inhibitor (86) 86
middle aged (81) 81
improves glycemic control (80) 80
linagliptin (80) 80
dipeptides - therapeutic use (78) 78
safety (78) 78
type 2 diabetes mellitus (78) 78
adamantane - therapeutic use (77) 77
diabetes therapy (76) 76
treatment outcome (76) 76
dipeptidyl-peptidase iv inhibitors - adverse effects (74) 74
dosage and administration (71) 71
glucose (71) 71
hypoglycemic agents - adverse effects (71) 71
adamantane - adverse effects (70) 70
alogliptin (70) 70
dipeptidyl peptidase-4 inhibitors (70) 70
diabetes mellitus (69) 69
research (69) 69
aged (68) 68
dipeptides - adverse effects (68) 68
glucagon-like peptide-1 (68) 68
efficacy (66) 66
double-blind (63) 63
care and treatment (62) 62
type-2 diabetes-mellitus (62) 62
drug therapy, combination (60) 60
clinical trials (59) 59
dapagliflozin (59) 59
animals (58) 58
hypoglycemia (57) 57
analysis (56) 56
hypoglycemic agents (56) 56
internal medicine (56) 56
adult (54) 54
dpp-4 inhibitors (54) 54
mellitus (54) 54
dipeptidyl-peptidase iv inhibitors - pharmacology (53) 53
hypoglycemic agents - administration & dosage (53) 53
risk factors (53) 53
dpp-4 inhibitor (52) 52
glycemic control (51) 51
therapy (49) 49
diabetes mellitus, type 2 - blood (48) 48
adamantane - administration & dosage (47) 47
insulin (46) 46
dipeptides - administration & dosage (44) 44
medicine & public health (44) 44
blood glucose - drug effects (42) 42
dipeptidyl-peptidase iv inhibitors - administration & dosage (42) 42
heart failure (41) 41
liraglutide (41) 41
medicine, general & internal (41) 41
double-blind method (40) 40
management (40) 40
diabetes mellitus, type 2 - complications (39) 39
metformin - therapeutic use (39) 39
randomized controlled-trial (38) 38
blood glucose - metabolism (37) 37
risk (37) 37
exenatide (36) 36
pharmacokinetics (36) 36
glycated hemoglobin a - metabolism (35) 35
glycosylated hemoglobin (35) 35
complications and side effects (34) 34
health aspects (34) 34
glp-1 (33) 33
medical research (33) 33
patients (32) 32
dextrose (31) 31
incretin (31) 31
add-on therapy (30) 30
studies (30) 30
beta-cell function (29) 29
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (29) 29
hypoglycemic agents - pharmacology (29) 29
metformin - administration & dosage (29) 29
adamantane - pharmacology (28) 28
dipeptidyl peptidase 4 - metabolism (28) 28
drug-naive patients (28) 28
hyperglycemia (28) 28
hypoglycemia - chemically induced (28) 28
peptidase (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (578) 578
German (7) 7
French (5) 5
Hungarian (3) 3
Czech (2) 2
Spanish (2) 2
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
by Clifton, Peter, MD, PhD
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
Abstract Purpose Although recent reports suggest an association between saxagliptin and an increased risk of admissions for heart failure, it is not clear... 
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | MYOCARDIAL-INFARCTION | SAXAGLIPTIN | HUMANS | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | IMPACT | CLINICAL-TRIALS | IMPROVES | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Data bases | Studies | Diabetes | Drug therapy | Acute coronary syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
by Barnett, Anthony H and Charbonnel, Bernard and Donovan, Mark and Fleming, Douglas and
Current Medical Research & Opinion, ISSN 0300-7995, 04/2012, Volume 28, Issue 4, pp. 513 - 523
Abstract Objective: To evaluate efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes (T2D) with inadequate glycemic control on... 
Dipeptidyl peptidase-4 inhibitor - DPP-4 - Hypoglycemia - Insulin - Saxagliptin - Type 2 diabetes | Dipeptidyl peptidase-4 inhibitor DPP-4 Hypoglycemia Insulin Saxagliptin Type 2 diabetes | Type 2 diabetes | MEDICINE, RESEARCH & EXPERIMENTAL | MANAGEMENT | EFFICACY | SAFETY | DPP-4 | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | Hypoglycemia | COMBINATION | Insulin | Dipeptidyl peptidase-4 inhibitor | MEDICINE, GENERAL & INTERNAL | PIOGLITAZONE | IMPROVES GLYCEMIC CONTROL | BASAL INSULIN | Saxagliptin | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Humans | Middle Aged | Insulin - administration & dosage | Male | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Metformin - adverse effects | Dipeptides - administration & dosage | Drug Therapy, Combination - methods | Hypoglycemic Agents - administration & dosage | Adolescent | Adult | Female | Aged | Metformin - administration & dosage | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text LC–MS/MS analysis of metformin, saxagliptin and 5‐hydroxy saxagliptin in human plasma and its pharmacokinetic study with a fixed‐dose formulation in healthy Indian subjects
by Shah, Priyanka A and Shah, Jaivik V and Sanyal, Mallika and Shrivastav, Pranav S
Biomedical Chromatography, ISSN 0269-3879, 03/2017, Volume 31, Issue 3, pp. np - n/a
A specific and rapid liquid chromatography–tandem mass spectrometry method is proposed for the simultaneous determination of metformin (MET), saxagliptin... 
metformin | saxagliptin | ion‐pair solid phase extraction | LC–MS/MS | human plasma | 5‐hydroxy saxagliptin | 5-hydroxy saxagliptin | ion-pair solid phase extraction | CHEMISTRY, ANALYTICAL | COMBINATION TABLETS | BIOCHEMISTRY & MOLECULAR BIOLOGY | SITAGLIPTIN | BIOCHEMICAL RESEARCH METHODS | TANDEM MASS-SPECTROMETRY | ANTIDIABETIC DRUGS | LIQUID-CHROMATOGRAPHIC METHOD | SINGLE-COMPONENT SAXAGLIPTIN | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | LC-MS/ MS | PHARMACOLOGY & PHARMACY | PHASE MICROEXTRACTION | BIOEQUIVALENCE | RAT PLASMA | Reproducibility of Results | Adamantane - blood | Humans | Solid Phase Extraction | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Dipeptides - blood | Metformin - blood | Adamantane - analogs & derivatives | Surface active agents | Metabolites | Ionization | Analysis | Nitriles | Liquid chromatography | Hypoglycemic agents | Dosage and administration | Sulfates | Mass spectrometry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Quantitative determination of metformin, saxagliptin and 5-hydroxy saxagliptin simultaneously by hydrophilic interaction liquid chromatography - electrospray ionization mass spectrometry and its application to a bioequivalence study with a single-pill combination in human
by Peng, Ying and Chang, Qingqing and Yang, Na and Gu, Shiyin and Zhou, Yi and Yin, Lifang and Aa, Jiye and Wang, Guangji and Sun, Jianguo
Journal of Chromatography B, ISSN 1570-0232, 04/2018, Volume 1081-1082, pp. 109 - 117
A simple, sensitive and specific hydrophilic interaction liquid chromatography coupled to electrospray ionization mass spectrometric (HILIC–MS) method was... 
Human plasma | Metformin | HILIC-MS/MS | 5-Hydroxy saxagliptin | Saxagliptin | CHEMISTRY, ANALYTICAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | EFFICACY | SAFETY | BIOCHEMICAL RESEARCH METHODS | ADD-ON THERAPY | PHARMACOKINETICS | COMPONENT SAXAGLIPTIN | TYPE-2 DIABETES-MELLITUS | RAT PLASMA | Medical research | Metabolites | Polyacrylamide | Formic acid | Medicine, Experimental | Nitriles | Liquid chromatography | Mass spectrometry | Organic acids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Eficacia y seguridad de los inhibidores de dipeptidil-peptidasa-4 (dpp-4) en pacientes con diabetes mellitus tipo 2: Un meta- análisis
by Park, Haesuk and Park, Chanhyun and Kim, Yoona and Rascati, Karen L
Annals of Pharmacotherapy, ISSN 1060-0280, 11/2012, Volume 46, Issue 11, pp. 1453 - 1469
Dipeptidyl peptidase-4 inhibitors | Sitagliptin | Linagliptin | Vildagliptin | Meta-analysis | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A11466 Protective effect of Saxagliptin, a DPP-4 inhibitor, on myocardial ischemia reperfusion injury in STZ induced diabetic rats
by Bisht, Khushboo and Vir, Arya Dharam and Rajeev, Malhotra
Journal of Hypertension, ISSN 0263-6352, 10/2018, Volume 36 Suppl 3, pp. e64 - e64
OBJECTIVES:To evaluate the effect of Saxagliptin (SAX), a DPP4 inhibitor, on myocardial ischemia-reperfusion (IR) injury in Streptozotocin (STZ) induced... 
Myocardial ischemia | Drug therapy | Patient outcomes | Reperfusion injury | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
by Golightly, Larry K and Drayna, Caitlin C and McDermott, Michael T
Clinical Pharmacokinetics, ISSN 0312-5963, 2012, Volume 51, Issue 8, pp. 501 - 514
  Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The... 
CD26-antigen-inhibitors | type-2-diabetes-mellitus | linagliptin | sitagliptin | vildagliptin | alogliptin | pharmacokinetics | saxagliptin | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ATC/DDD classification
WHO Drug Information, ISSN 1010-9609, 09/2018, Volume 32, Issue 4, p. 556
Aprepitant | Hydrochlorothiazide | Dapagliflozin | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ammonolysis of -2-pyrroline with immobilized Candida antarctica lipase B in a packed bed reactor
by Tirunagari, Harini and Kuna, Lavanya and Shalini, Basetty and Thenkrishnan, Kumaraguru
Process Biochemistry, ISSN 1359-5113, 02/2018, Volume 65, p. 109
Conversion of (5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-2-pyrroline to its corresponding amide, an important intermediate in the synthesis of the... 
Ammonia | Biological products | Lipase | Enzyme kinetics | Chromatography | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text The Strecker reaction coupled to Viedma ripening: A simple route to highly hindered enantiomerically pure amino acids
by Baglai, Iaroslav and Leeman, Michel and Wurst, Klaus and Kaptein, Bernard and Kellogg, Richard M and Noorduin, Willem L
Chemical Communications, ISSN 1359-7345, 2018, Volume 54, Issue 77, pp. 10832 - 10834
The Strecker reaction is broadly used for the preparation of -amino acids. However, control of enantioselectivity remains challenging. We here couple the... 
CRYSTALLIZATION | PEPTIDASE-IV INHIBITOR | AMPLIFICATION | HOMOCHIRALITY | SAXAGLIPTIN | DERACEMIZATION | STATE | INTERMEDIATE | DERACEMISATION | DERIVATIVES | CHEMISTRY, MULTIDISCIPLINARY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-[kappa]B
by Ma, Suxia and Bai, Zhifeng and Wu, Huiying and Wang, Wei
European Journal of Pharmacology, ISSN 0014-2999, 05/2019, Volume 851, p. 186
Diabetes-associated cardiovascular complications are the leading cause of death for diabetic patients. Dipeptidyl peptidase 4 (DPP-4) inhibitor agents, known... 
Oxidases | Phosphates | Niacinamide | Diabetics | Interleukins | Low density lipoproteins | Lectins | Cardiology | Saxagliptin | Endothelium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis
by Phan, Kevin and Charlton, Olivia and Smith, Saxon D
Australasian Journal of Dermatology, ISSN 0004-8380, 2019
There have been a number of case reports and small clinical series reporting the potential association between dipeptidyl peptidase-4 inhibitors (DPPIs) for... 
bullous pemphigoid | linagliptin | sitagliptin | gliptin | peptidyl peptidase-4 inhibitor | vildagliptin | saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin
by Boulton, David W and Kasichayanula, Sreeneeranj and Keung, Chi Fung (Anther) and Arnold, Mark E and Christopher, Lisa J and Xu, Xiaohui (Sophia) and Lacreta, Frank
British Journal of Clinical Pharmacology, ISSN 0306-5251, 03/2013, Volume 75, Issue 3, pp. 763 - 768
Accelerator mass spectrometry (AMS) | Dapagliflozin | Intravenous | Absolute bioavailability | C-microdose | Microtracer | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Saxagliptin levels and its pharmacokinetic application in presence of sucralse in animals serum by HPLC method
by Dayyih, Wael Abu and Tamimi, Lina and Mallah, Eyad and Mansour, Kenza and Arafat, Tawfiq and Bustami, Mona
International Journal of Pharmacy and Pharmaceutical Sciences, 2015, Volume 7, Issue 9, pp. 243 - 250
Sucralose | Interaction | HPLC | Pharmacokinetic | Saxagliptin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes
by Rosenstock, J and Sankoh, S and List, J. F
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2008, Volume 10, Issue 5, pp. 376 - 386
Aim:  Enhancing the physiologic actions of the endogenous incretin hormones, glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide, by... 
type 2 diabetes | incretin | saxagliptin (BMS‐477118) | GLP‐1 | HbA1c | DPP‐4 | GIP | Type 2 diabetes | Incretin | GLP-1 | DPP-4 | Saxagliptin (BMS-477118) | GLYCEMIC CONTROL | ADULTS | MELLITUS | INSULIN | BMS-477118 | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | saxagliptin (BMS-477118) | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Adult | Female | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Blood Glucose - drug effects | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension
by Kadowaki, Takashi and Muto, Satsuki and Ouchi, Yoshiumi and Shimazaki, Ryutaro and Seino, Yutaka
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 12/2017, Volume 18, Issue 18, pp. 1903 - 1919
Background: We examined the efficacy and safety of saxagliptin as an add-on to insulin in Japanese patients with type 2 diabetes mellitus. Research design and... 
Dipeptidyl peptidase-4 inhibitors | type 2 diabetes mellitus | elderly patients | saxagliptin | insulin | Japanese | PEPTIDASE-4 INHIBITOR SAXAGLIPTIN | METFORMIN | 12-WEEK | SITAGLIPTIN | RENAL IMPAIRMENT | ADD-ON THERAPY | DIPEPTIDYL PEPTIDASE-4 | VILDAGLIPTIN | TARGETS | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Novel RP-HPLC method development and validation for the simultaneous estimation of saxagliptin and glimepiride
by Upadhyay, Navneet Kumar and Rathore, Charul and Sapra, Sameer and Negi, Poonam
International Journal of Applied Pharmaceutics, ISSN 0975-7058, 05/2018, Volume 10, Issue 3, pp. 151 - 156
Validation | Glimepiride | Simultaneous determination | Liquid chromatography | Saxagliptin
Journal Article
Details down arrow
18. Full Text Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes
by Lundkvist, Per and Pereira, Maria J and Kamble, Prasad G and Katsogiannos, Petros and Langkilde, Anna Maria and Esterline, Russell and Johnsson, Eva and Eriksson, Jan W
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 01/2019, Volume 104, Issue 1, pp. 193 - 201
Context: The mechanism mediating sodium glucose cotransporter-2 (SGLT2) inhibitor-associated increase in glucagon levels is unknown. Objective: To assess... 
INSULIN | ADD-ON | HYPERGLYCEMIA | DAPAGLIFLOZIN | LIRAGLUTIDE | SAXAGLIPTIN | ENDOCRINOLOGY & METABOLISM | SECRETION | COTRANSPORTER 2 INHIBITION | LOWERING DRUGS | PEPTIDE-1 RECEPTOR AGONISTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text DPP‐4 inhibitors and their potential role in the management of type 2 diabetes
by BARNETT, A
International Journal of Clinical Practice, ISSN 1368-5031, 11/2006, Volume 60, Issue 11, pp. 1454 - 1470
Summary The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to control blood glucose by increasing the active levels of incretin... 
saxagliptin | DPP‐4 inhibitor | sitagliptin | type 2 diabetes | vildagliptin | Type2 diabetes | Sitagliptin | Vildagliptin | DPP-4 inhibitor | Saxagliptin | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | HEALTHY-SUBJECTS | EXENATIDE EXENDIN-4 | SAXAGLIPTIN BMS-477118 | INSULIN SENSITIVITY | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | MEDICINE, GENERAL & INTERNAL | GLUCAGON-LIKE PEPTIDE-1 | METFORMIN-TREATED PATIENTS | Hypoglycemic Agents - therapeutic use | Triazoles - adverse effects | Dipeptides - therapeutic use | Dipeptides - adverse effects | Humans | Glycoproteins - antagonists & inhibitors | Dipeptidyl Peptidase 4 | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Blood Glucose - drug effects | Animals | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Adamantane - therapeutic use | Pyrrolidines | Models, Animal | Nitriles | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Type 2 diabetes | Diabetes therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
by Rosenstock, Julio and Perkovic, Vlado and Johansen, Odd Erik and Cooper, Mark E and Kahn, Steven E and Marx, Nikolaus and Alexander, John H and Pencina, Michael and Toto, Robert D and Wanner, Christoph and Zinman, Bernard and Woerle, Hans Juergen and Baanstra, David and Pfarr, Egon and Schnaidt, Sven and Meinicke, Thomas and George, Jyothis T and Von Eynatten, Maximilian and McGuire, Darren K and CARMELINA Investigators and for the CARMELINA Investigators
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4)... 
KIDNEY-DISEASE | MORTALITY | MEDICINE, GENERAL & INTERNAL | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Randomization | Vascular diseases | Safety engineering | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Online First | Original Investigation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights